Figure 2

(a) Overall survival (OS) of patients with normal karyotype (NK) and with pure hyperdiploid karyotype (HDK) AML from the time of diagnosis. (b) OS of patients with HDK and with complex aberrant karyotype AML with ⩾3 aberrations (CK+adv) of which at least one aberration predicts an adverse risk per se, but without HDK and t(9;11) from the time of diagnosis. (c) OS of patients with NK and with complex aberrant karyotype with t(9;11)(p21–22;q23) from the time of diagnosis. (d) OS of patients with NK, with complex aberrant karyotype with three unrelated abnormalities but without HDK, t(9;11), and specific adverse-risk aberrations (CK3), with complex aberrant karyotype with ⩾4 unrelated abnormalities but without HDK, t(9;11), and specific adverse-risk aberrations (CK4). Median OS is depicted in the respective table. Cox regression (*, hazard ratio (HR), P-value) was performed applying age, WBC, LDH and the type of AML (AML with antecedent myelodysplastic syndrome and therapy-related AML) as co-variables. Abbreviation: LDH, lactate dehydrogenase.